ALTERITY THERAPEUTICS LTD (ATHE) Form 6-K — Aug 13, 2026
On August 12, 2026, Alterity Therapeutics announced that the USPTO granted a new U.S. composition of matter patent for ATH434, the company's lead clinical asset, extending patent protection to at least 2045. The patent covers the crystalline mesylate salt form of ATH434 that was used in the company's Phase 2 MSA trials and will be used in the planned Phase 3 study, with Phase 3 trial activities in Multiple System Atrophy targeted to begin by year-end 2026. The patent is expected to be listed in the FDA Orange Book upon regulatory approval.
Key figures
- Msa us patients
- up to 50,000
- Parkinsons us patients
- nearly 1,000,000
- Phase3 initiation target
- year-end 2026
- Patent protection through
- at least 2045
- Parkinsons worldwide patients
- more than 10,000,000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.